Anti-CD70 CAR mRNA-LNP

CD70 (Cluster of Differentiation 70), encoded by the CD70 gene, is a cytokine belonging to the tumor necrosis factor (TNF) ligand family. This cytokine is the surface antigen and ligand of TNFRSF27/CD27. It is primarily expressed on highly activated T and B cells, as well as NK cells and mature dendritic cells. CD70 expression on T and B cells is stimulated by triggering T and B cell receptors and can be upregulated by several cytokines such as IL-1α, IL-2, IL-12, GM-CSF and TNF-α. As a co-stimulatory molecule, CD70 plays an important role in regulating immune system activation, in particular by improving the activation, proliferation and survival of T and B cells, resulting in a more effective immune response. CD70 has been shown to be overexpressed in several types of cancer, including Hodgkin's and non-Hodgkin's lymphomas, as well as certain types of solid tumors. Overexpression of CD70 in cancer cells correlates with cell proliferation and survival, and inhibits apoptosis, in cancer progression. Therefore, CD70 is considered as a possible target for the treatment of CD70-positive lymphomas. This product is designed as a tool for the delivery and expression of anti-CD70 CAR mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of anti-CD70 CAR mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The anti-CD70 CAR in this product is approximately 56 kD and consists of anti-CD70 scFv (single-chain variable fragment) linked to a second-generation CAR (chimeric antigen receptor) containing the CD8 hinge and transmembrane domain and 4-1BB and CD3ζ signaling domains. The full-length amino acid sequence of this anti-CD70 CAR mRNA-LNP product is available upon request.